|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||46.90 - 47.32|
|52 Week Range||40.38 - 55.84|
|Beta (3Y Monthly)||0.46|
|PE Ratio (TTM)||27.92|
|Forward Dividend & Yield||0.76 (1.62%)|
|1y Target Est||57.08|
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
European stocks were on course to notch their best weekly performance in two months on Friday as a jump in shares of French pharma giant Sanofi added to the positive mood created by expectations of more moves by central banks to stir growth. France's CAC 40 outperformed its peers with a 1.2% rise, helped by a 4.5% jump in Sanofi after the company appointed Swiss rival Novartis' executive Paul Hudson as its new boss.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll evaluate Novozymes A/S (CPH:NZYM B) to determine whether it could have potential as an inve...
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll apply a basic P/E ratio analysis to Novozymes A/S's (CPH:NZYM B), to help you decide if the stock is worth further research...
Novozymes has signed up two new partners for its biological agriculture business (BioAg), adding to its previously exclusive partnership with German chemicals giant Bayer in a drive to boost growth. The Danish company is the world's largest maker of industrial enzymes and with BioAg produces microbes such as bacteria and fungi to protect plants from pests and help them to grow faster. It will continue a close innovation and commercial partnership with Bayer within corn and soy, Novozymes said late on Thursday, as it presented two new partners - Univar Solutions and UPL.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Analyzing Novozymes A/S's (CPH:NZYM B) track record of past performance is a valuable exercise for investors. It enables us t...
A look at the shareholders of Novozymes A/S (CPH:NZYM B) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Novozymes A/S Class B (OTC PINK: NVZMY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 10, 2018 at 9:00 AM Eastern ...
The factors that are pulling in our business are slightly different from what we expected," Peder Holk Nielsen, the CEO of Novozymes told "Squawk Box Europe" on Friday. Earnings before interest and tax (EBIT) for the quarter came in at 957 million Danish krone ($147 million) with its household care sector showing particular weakness. Shares of global biotechnology company Novozymes slumped Friday morning after reporting second-quarter earnings that missed analysts' expectations.